Cargando…
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost–Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study
PURPOSE: This study assessed the feasibility and compliance of induction chemotherapy with gemcitabine and cisplatin followed by simultaneous integrated boost–intensity modulated radiotherapy (SIB-IMRT) with concurrent gemcitabine in patients with locally advanced unresectable pancreatic cancer. MAT...
Autores principales: | Woo, Sang Myung, Kim, Min Kyeong, Joo, Jungnam, Yoon, Kyong-Ah, Park, Boram, Park, Sang-Jae, Han, Sung-Sik, Lee, Ju Hee, Hong, Eun Kyung, Kim, Yun-Hee, Moon, Hae, Kong, Sun-Young, Kim, Tae Hyun, Lee, Woo Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654154/ https://www.ncbi.nlm.nih.gov/pubmed/28111423 http://dx.doi.org/10.4143/crt.2016.495 |
Ejemplares similares
-
RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin
por: Chun, Jung Won, et al.
Publicado: (2021) -
DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study
por: Woo, Sang Myung, et al.
Publicado: (2017) -
Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin
por: You, Min su, et al.
Publicado: (2019) -
Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
por: Lee, Sang Hoon, et al.
Publicado: (2020) -
High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin
por: Huh, Gunn, et al.
Publicado: (2020)